Request for information invites feedback on disposal products to help reduce misuse of unused medications.
The U.S. Food and Drug Administration (FDA) has issued a Request for Information (RFI) seeking public comment on potential standards for in-home opioid disposal products as part of ongoing efforts to address opioid misuse. Manufacturers of opioid analgesics must currently provide prepaid mail-back envelopes to pharmacies and other dispensers so unused medications can be returned safely. The agency is now considering whether companies should also provide disposal systems that allow patients to neutralize unused opioids at home.
“Having unused opioids laying around at home can be a significant risk to those struggling with opioids and can be a gateway for opioid-naïve family members,” said FDA Commissioner Marty Makary. “We need to develop creative ways to address opioid misuse and abuse.”
Existing FDA guidance encourages people to use drug take-back programs, return medications by mail, or, in some cases, flush certain high-risk drugs.
As the Lord Leads, Pray with Us…
- For Commissioner Makary and FDA staff and researchers as they seek to improve medication safety and public health.
- For Secretary Kennedy and Health and Human Services officials working to address opioid misuse and substance-use disorders.
- For families and communities affected by opioid addiction, and for protection, recovery resources, and support for those seeking treatment.
Sources: Food and Drug Administration
